Proteomic and metabolic prediction of response to therapy in gastric cancer

doi:10.3748/wjg.v20.i38.13648

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 38

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7758)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

480

WORD

245

HTML

4736

Figures (1-3)

161

Tables (1-1)

158

Sum=5780

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

993

Download

985

Sum=1978

Oct 14, 2014 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 14, 2014; 20(38): 13648-13657
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13648

Proteomic and metabolic prediction of response to therapy in gastric cancer

Michaela Aichler, Birgit Luber, Florian Lordick, Axel Walch

Michaela Aichler, Research Unit Analytical Pathology - Institute of Pathology, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany

Birgit Luber, Institute of Pathology, Technische Universität München, Trogerstraße 18, 81675 München, Germany

Florian Lordick, University Cancer Center Leipzig, University of Leipzig, Liebigstraße 20, 04103 Leipzig, Germany

Axel Walch, Research Unit Analytical Pathology, Institute of Pathology, Helmholtz Zentrum München, German Research Centre for Environmental Health, 85764 Neuherberg, Germany

Author contributions: All authors contributed in writing this review.

Supported by Ministry of Education and Research of the Federal Republic of Germany, Grant No. 0315508A and No. 01IB10004E (to AW), SYS-Stomach to BL, FL and AW); and the Deutsche Forschungsgemeinschaft, Grant No. HO 1258/3-1, No. SFB 824 TP Z02 and No. WA 1656/3-1 (to AW)

Correspondence to: Axel Walch, MD, Professor, Research Unit Analytical Pathology, Institute of Pathology, Helmholtz Zentrum München, German Research Centre for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. axel.walch@helmholtz-muenchen.de

Telephone: +49-89-31872739 Fax: +49-89-31873349

Received: December 9, 2013
Revised: February 4, 2014
Accepted: June 13, 2014
Published online: October 14, 2014

Core Tip

Core tip: The prognosis of patients diagnosed with gastric cancer is still poor. Cytotoxic treatment and targeted therapies have improved the prognosis of patients. However, patients do not benefit equally from these treatment options. The ability to predict whether patients will respond to specific therapies would be of particular value and would allow for stratifying patients for personalized treatment strategies. In this review, we discuss the status of targeted therapies for gastric cancer, as well as proteomic and metabolic methods for investigating biomarkers for therapy response prediction in gastric cancer.